U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C26H29N3O6.ClH
Molecular Weight 515.9868
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NICARDIPINE HYDROCHLORIDE

SMILES

CC1=C(C(c2cccc(c2)N(=O)=O)C(=C(C)N1)C(=O)OCCN(C)Cc3ccccc3)C(=O)OC.Cl

InChI

InChIKey=AIKVCUNQWYTVTO-UHFFFAOYSA-N
InChI=1S/C26H29N3O6.ClH/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19;/h5-12,15,24,27H,13-14,16H2,1-4H3;1H

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.4609
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C26H29N3O6
Molecular Weight 479.526
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.drugbank.ca/drugs/DB00622 | https://www.drugs.com/cdi/nicardipine.html | https://www.ncbi.nlm.nih.gov/pubmed/2772808 | http://reference.medscape.com/drug/cardene-iv-nicardipine-342377

Nicardipine is a potent calcium channel blockader with marked vasodilator action used to treat high blood pressure and angina. By deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, nicardipine inhibits the influx of extracellular calcium across the myocardial and vascular smooth muscle cell membranes The decrease in intracellular calcium inhibits the contractile processes of the myocardial smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.

Originator

Sources: JP 49109384

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
0.25 µM [IC50]
2.66 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Primary
CARDENE

Approved Use

I. Stable Angina Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. II. Hypertension Nicardipine hydrochloride capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive drugs. In administering nicardipine hydrochloride it is important to be aware of the relatively large peak to trough differences in blood pressure effect. (See .) DOSAGE AND ADMINISTRATION

Launch Date

5.9866559E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
35.1 ng/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
64.1 ng/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.9 ng/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
18.8 ng/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1426.2 ng × h/mL
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2996.1 ng × h/mL
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
7510.7 ng × h/mL
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
846.3 ng × h/mL
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.3 h
1 mg/h steady-state, intravenous
dose: 1 mg/h
route of administration: Intravenous
experiment type: STEADY-STATE
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14 h
2 mg/h other, intravenous
dose: 2 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
17.9 h
4 mg/h other, intravenous
dose: 4 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
20.6 h
0.5 mg/h other, intravenous
dose: 0.5 mg/h
route of administration: Intravenous
experiment type: OTHER
co-administered:
NICARDIPINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
5%
NICARDIPINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Other AEs: Slurred speech, Hypotension...
Other AEs:
Slurred speech
Hypotension (marked)
Bradycardia
Palpitations
Flushing
Drowsiness
Confusion
Sources: Page: p.21
100 mg 2 times / day multiple, oral
Recommended
Dose: 100 mg, 2 times / day
Route: oral
Route: multiple
Dose: 100 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Disc. AE: Hypotension, Headache...
AEs leading to
discontinuation/dose reduction:
Hypotension
Headache
Tachycardia
Sources: Page: p.21
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Disc. AE: Rash, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Rash (0.9%)
Diarrhea (0.9%)
Tachycardia (0.9%)
Blurred vision (0.6%)
Chest pain (0.6%)
Face edema (0.6%)
Myocardial infarct (0.6%)
Vasodilatation (0.6%)
Vomiting (0.6%)
Sources: Page: p.10
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Disc. AE: Headache, Palpitation...
AEs leading to
discontinuation/dose reduction:
Headache (2.5%)
Palpitation (2.2%)
Dizziness (1.9%)
Asthenia (1.9%)
Pedal edema (1.2%)
Nausea (1.2%)
Sources: Page: p.9
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
Disc. AE: Angina...
AEs leading to
discontinuation/dose reduction:
Angina
Sources: Page: p.5
AEs

AEs

AESignificanceDosePopulation
Bradycardia
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Confusion
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Drowsiness
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Flushing
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Palpitations
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Slurred speech
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Hypotension marked
2160 mg single, oral
Overdose
Dose: 2160 mg
Route: oral
Route: single
Dose: 2160 mg
Sources: Page: p.21
unhealthy
n = 1
Health Status: unhealthy
Condition: Hypertension
Population Size: 1
Sources: Page: p.21
Headache Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Hypotension Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Tachycardia Disc. AE
15 mg/h single, intravenous (max)
Recommended
Dose: 15 mg/h
Route: intravenous
Route: single
Dose: 15 mg/h
Sources: Page: p.21
unhealthy
n = 144
Health Status: unhealthy
Condition: Hypertension
Population Size: 144
Sources: Page: p.21
Blurred vision 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Chest pain 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Face edema 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Myocardial infarct 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vasodilatation 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Vomiting 0.6%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Diarrhea 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Rash 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Tachycardia 0.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.10
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.10
Nausea 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Pedal edema 1.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Asthenia 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Dizziness 1.9%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Palpitation 2.2%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Headache 2.5%
Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.9
unhealthy
n = 322
Health Status: unhealthy
Condition: Hypertension
Population Size: 322
Sources: Page: p.9
Angina Disc. AE
60 mg 2 times / day multiple, oral (max)
Studied dose
Dose: 60 mg, 2 times / day
Route: oral
Route: multiple
Dose: 60 mg, 2 times / day
Sources: Page: p.5
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources: Page: p.5
OverviewDrug as perpetrator​

Drug as perpetrator​

Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of nicardipine on left ventricular function and energetics in man.
1986 Mar
Efficacy and safety of nicardipine for chronic, stable angina pectoris: a multicenter randomized trial.
1986 Oct 1
A comparison of nine calcium ion antagonists and propranolol: exercise tolerance, heart rate and ST-segment changes in patients with chronic stable angina pectoris.
1987
Nicardipine in the treatment of essential hypertension controlled 6-month-study comparing nicardipine with propranolol at rest and during exercise.
1987
An evaluation of the pharmacodynamics and pharmacokinetics of nicardipine combined with enalapril in essential hypertension.
1987 Dec
Central interactions between dihydropyridines and cholinergic systems in the control of blood pressure in rat.
1987 Dec 1
Nicardipine and urinary retention.
1987 Dec 18
Metabolic and hemodynamic effects of nicardipine during pacing-induced angina pectoris.
1987 Feb 1
Hemodynamic and cardiac metabolic changes during nicardipine-induced myocardial ischemia.
1988
Erythromelalgia induced by nicardipine.
1989 Jul 29
Erythromelalgia induced by nicardipine.
1989 Jun 10
Erythromelalgia induced by nicardipine (inverse Raynaud's phenomenon?).
1989 May 6
Nicardipine decreases blood pressure and heart rate at nucleus tractus solitarii of spontaneously hypertensive rats.
1989 Nov
The influence of nicardipine on left ventricular hemodynamics and compliance in patients with coronary heart disease.
1990
[Blood pressure monitoring in aged hypertensive patients treated with sustained-release nicardipine or nifedipine].
1990 Dec 8
Nicardipine reduces the cardio-respiratory toxicity of intravenously administered bupivacaine in rats.
1990 Nov
Inhibitory effects of diltiazem, verapamil, nifedipine, and nicardipine on sympathetic tachycardia in decentralized hearts of anesthetized dogs.
1990 Oct
Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: a 1-year follow-up.
1991
Nicardipine protects against chronic ethanol- or haloperidol-induced supersensitivity to apomorphine-induced aggression.
1991 Aug
Heterogeneous interference of nicardipine, verapamil, and diltiazem with forearm arteriolar responsiveness to adrenergic stimulation in hypertensive patients.
1991 Jul
Nicardipine and vascular hypertrophy.
1991 Jul
[A comparison of the endocrine effects of hypotension induced by nicardipine with those by sodium nitroprusside in dogs].
1991 Jul
Co-suppression by nicardipine, a calcium antagonist, of induction of microsomal lauric acid hydroxylation with peroxisome proliferation in clofibrate-treated rat liver.
1991 May
Effects of nicardipine on the metabolic responses to food and exercise.
1992 Apr
Nicardipine in the prevention of spasm-induced neurological deficits after subarachnoid hemorrhage: a dose-ranging study.
1992 Jul
Hemodynamic effects of nicardipine-induced hypotension during enflurane/nitrous oxide anesthesia in man.
1992 Oct
Intravenous nicardipine in hypertensive children.
1993 Sep
Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions.
2000 Feb-Mar
Interaction of digoxin with antihypertensive drugs via MDR1.
2002 Feb 15
Profound sinus bradycardia after intravenous nicardipine.
2002 Jul
Inactivation of aconitase during the apoptosis of mouse cerebellar granule neurons induced by a deprivation of membrane depolarization.
2003 Feb 15
Dihydropyridine Ca2+ channel antagonists and agonists block Kv4.2, Kv4.3 and Kv1.4 K+ channels expressed in HEK293 cells.
2003 Jun
Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze.
2003 Mar
Inhibitory effects of carvedilol on calcium channels in vascular smooth muscle cells.
2003 Nov
Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes.
2005 Aug
Exposure to a moderate intensity static magnetic field enhances the hypotensive effect of a calcium channel blocker in spontaneously hypertensive rats.
2005 Dec
Anaphylactic shock: a form of distributive shock without inhibition of oxygen consumption.
2005 Jul
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes.
2005 May
Quantitative PCR assay for cytochromes P450 2B and 3A induction in rat precision-cut liver slices: correlation study with induction in vivo.
2005 Sep-Oct
Endogenous release of secretin from the hypothalamus.
2006 Jul
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers.
2007 Jan
Treatment of cerebral vasospasm with biocompatible controlled-release systems for intracranial drug delivery.
2008 Dec
Comparison between atosiban and nicardipine in inducing hypotension during in-utero transfers for threatening premature delivery.
2010 Jun
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.
2011 Jul 14
Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma.
2011 Mar 1
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Sample Use Guides

Hypertension. PO: 20-40 mg (conventional) q8hr or 30-60 mg (extended release) q12hr; IV: 5 mg/hr by slow infusion (50 mL/hr) initially; may be increased by 2.5 mg/hr every 15 minutes; not to exceed 15 mg/hr Chronic Stable Angina. 20-40 mg (conventional) PO q8h
Route of Administration: Other
The growth effects of EGF and nicardipine on U251MG cultured in serum-free and serum-supplemented (10% fetal bovine serum, FBS) medium respectively were observed by MTT colorimeritric analysis. EGF significantly enhanced the growth of U251MG cells in a dose-dependent manner in serum-free medium. The maximal effect was seen at 20 ng/ml. The effects of EGF approximated those obtained in 10% FBS. Nicardipine decreased U251MG cell proliferation, especially in serum-supplemented medium, and completely blocked the growth-stimulated effects of EGF. The combined effects of EGF (10 ng/ml) and nicardipine equaled those of nicardipine alone.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:06:39 UTC 2021
Edited
by admin
on Fri Jun 25 21:06:39 UTC 2021
Record UNII
K5BC5011K3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NICARDIPINE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
NICARPIN
Common Name English
NICARDIPINE HYDROCHLORIDE [JAN]
Common Name English
BARIZIN
Common Name English
RYDENE
Common Name English
RS-69216-XX-07-0
Code English
NICODEL
Common Name English
RS-69216
Code English
NICARDAL
Common Name English
RANVIL
Common Name English
LOXEN
Common Name English
2-(BENZYLMETHYLAMINO)ETHYL METHYL 1,4-DIHYDRO-2,6-DIMETHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE MONOHYDROCHLORIDE
Systematic Name English
NICARDIPINE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
LECIBRAL
Common Name English
NICARDIPINE HYDROCHLORIDE [USP-RS]
Common Name English
CARDEPINE
Brand Name English
LECIBRA
Common Name English
PERDIPINA
Common Name English
YC-93
Code English
NIMICOR
Common Name English
VASODIN
Common Name English
NICARDIPINE HYDROCHLORIDE [VANDF]
Common Name English
PERDIPINE
Brand Name English
NICARDIPINE HYDROCHLORIDE [USAN]
Common Name English
NICAPRESS
Common Name English
NICARDIPINE HCL
Common Name English
NICANT
Common Name English
NICARDIPINE HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
NICARDIPINE HYDROCHLORIDE [EP MONOGRAPH]
Common Name English
2,6-DIMETHYL-4-(3-NITROPHENYL)-1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID 3-(2-(N-BENZYL-N-METHYLAMINO))-ETHYL ESTER 5-METHYL ESTER HYDROCHLORIDE
Common Name English
DACAREL
Common Name English
NICARDIPINE HYDROCHLORIDE [WHO-DD]
Common Name English
VASONASE
Common Name English
RS-69216XX07-0
Code English
NSC-757855
Code English
RYCARDEN
Common Name English
NERDIPINA
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, 3-METHYL 5-(2-(METHYL(PHENYLMETHYL)AMINO)ETHYL) ESTER, HYDROCHLORIDE (1:1)
Common Name English
NICARDIPINE HYDROCHLORIDE [MART.]
Common Name English
3,5-PYRIDINEDICARBOXYLIC ACID, 1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITROPHENYL)-, METHYL 2-(METHYL(PHENYLMETHYL)AMINO)ETHYL ESTER, MONOHYDROCHLORIDE
Common Name English
NICARDIPINE HYDROCHLORIDE [MI]
Common Name English
LESCODIL
Common Name English
CARDENE
Brand Name English
RIDENE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
Code System Code Type Description
NCI_THESAURUS
C29840
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
USP_CATALOG
1463224
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY USP-RS
CAS
54527-84-3
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
MERCK INDEX
M7850
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY Merck Index
EVMPD
SUB03420MIG
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
FDA UNII
K5BC5011K3
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
DRUG BANK
DBSALT000499
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
RXCUI
235230
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY RxNorm
EPA CompTox
54527-84-3
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
PUBCHEM
41114
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
ECHA (EC/EINECS)
259-198-4
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
ChEMBL
CHEMBL1484
Created by admin on Fri Jun 25 21:06:39 UTC 2021 , Edited by admin on Fri Jun 25 21:06:39 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY